Immunomedics

FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Flag link:
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Motley Fool
Immunomedics
ASCO 2018
sacituzumab govitecan
breast cancer
Flag link:
After months of searching, Immunomedics lines up Celgene vet Pehl as its new CEO
After months of searching, Immunomedics lines up Celgene vet Pehl as its new CEO
Fierce Biotech
Immunomedics
Celgene
Pharma CEOs
Michael Pehl
Flag link:
Will Seattle Genetics' Deal With Immunomedics Get Scuttled?
Will Seattle Genetics' Deal With Immunomedics Get Scuttled?
Motley Fool
Seattle Genetics
Immunomedics
IMMU-132
Flag link:
Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News
Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News
TheStreet.com
Immunomedics
Seattle Genetics
M&A
solid tumors
Adcetris
Flag link:
7 Biopharma Companies That Destroyed Shareholders Last Week
7 Biopharma Companies That Destroyed Shareholders Last Week
24/7 Wall St
ProNai
Adamis Pharmaceuticals
Ocular Therapeutics
Mirati Therapeutics
Immunomedics
Valeant Pharmacueticals
Biogen
Flag link:
Immunomedics' ASCO Letdown
Immunomedics' ASCO Letdown
Motley Fool
ASCO 2016
Immunomedics
Flag link:
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Motley Fool
biotech
ASCO 2016
Biogen
Immunomedics
AbbVie
Juno Therapeutics
Kite Pharma
Flag link:
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
TheStreet.com
Immunomedics
triple negative breast cancer
ASCO 2016
IMMU-132
Flag link:
10 Worst NASDAQ Biotech Stocks in the Third Quarter
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
Flag link:
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
24/7 Wall St
biotech
ASCO
Immunogen
Exelixis
Oncothyreon
CTI BioPharma
Immunomedics
Vascular Biogenics
Flag link:
16 Biotech Stocks Moving Off The ASCO Conference
16 Biotech Stocks Moving Off The ASCO Conference
Yahoo/Benzinga
biotech
ASCO
Bristol-Myers Squibb
Immunogen
Oncothyreon
Clovis Oncology
CTI BioPharma
Exelixis
Roche
Amgen
AstraZeneca
Puma Biotechnology
Vascular Biogenics
Immunomedics
Momenta
Eli Lilly
Juno Therapeutics
Express Scripts
Flag link:
6 Key Cancer Winners From ASCO Presentations
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Flag link:
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Yahoo
Immunomedics
chemotherapy
breast cancer
lung cancer
esophageal cancer
colorectal cancer
sacituzumab govitecan
Flag link:
Immunomedics Inc announces orphan drug designation for IMMU-132 for Pancreatic Cancer Therapy
Immunomedics Inc announces orphan drug designation for IMMU-132 for Pancreatic Cancer Therapy
Reuters
IMMU-132
orphan drugs
Immunomedics
pancreatic cancer
Flag link:
Immunomedics Reports Final Efficacy Results of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer
Immunomedics Reports Final Efficacy Results of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer
Yahoo/Globe Newswire
Immunomedics
pancreatic cancer
clivatuzumab tetraxetan
gemcitabine
Flag link:
Immunomedics' (IMMU) CEO Cynthia Sullivan on F3Q 2014 Results - Earnings Call Transcript
Immunomedics' (IMMU) CEO Cynthia Sullivan on F3Q 2014 Results - Earnings Call Transcript
Seeking Alpha
Immunomedics
earnings
Flag link:
Immunomedics reports results from three IMMU-130 phase I trials
Immunomedics reports results from three IMMU-130 phase I trials
Yahoo/Fly on the Wall
Immunomedics
IMMU-130
colorectal cancer
Flag link:
Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
24/7 Wall St
Celldex Therapeutics
Immunomedics
Keryx
Merrimack Pharmaceuticals
Protalix BioTherapeutics
Flag link:
A Look Back at Immunomedics' Volatile but Rewarding 2013
A Look Back at Immunomedics' Volatile but Rewarding 2013
Motley Fool
Immunomedics
Flag link:

Pages